HomeCompareNDP vs MRK

NDP vs MRK: Dividend Comparison 2026

NDP yields 6.24% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $10.0K in total portfolio value
10 years
NDP
NDP
● Live price
6.24%
Share price
$40.40
Annual div
$2.52
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.8K
Annual income
$0.64
Full NDP calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — NDP vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNDPMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NDP + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NDP pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NDP
Annual income on $10K today (after 15% tax)
$530.26/yr
After 10yr DRIP, annual income (after tax)
$0.54/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $807.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NDP + MRK for your $10,000?

NDP: 50%MRK: 50%
100% MRK50/50100% NDP
Portfolio after 10yr
$25.8K
Annual income
$475.47/yr
Blended yield
1.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NDP
No analyst data
Altman Z
1.7
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NDP buys
0
MRK buys
0
No recent congressional trades found for NDP or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNDPMRK
Forward yield6.24%3.25%
Annual dividend / share$2.52$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR-50%8.2%
Portfolio after 10y$20.8K$30.7K
Annual income after 10y$0.64$950.29
Total dividends collected$635.00$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NDP vs MRK ($10,000, DRIP)

YearNDP PortfolioNDP Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,012$311.92$11,192$351.54$180.00MRK
2$11,943$160.51$12,524$392.70$581.00MRK
3$12,861$81.35$14,015$438.65$1.2KMRK
4$13,802$40.93$15,682$489.96$1.9KMRK
5$14,788$20.53$17,547$547.23$2.8KMRK
6$15,834$10.28$19,632$611.16$3.8KMRK
7$16,947$5.14$21,963$682.53$5.0KMRK
8$18,136$2.57$24,571$762.18$6.4KMRK
9$19,407$1.29$27,486$851.08$8.1KMRK
10$20,766$0.64$30,745$950.29$10.0KMRK

NDP vs MRK: Complete Analysis 2026

NDPStock

Tortoise Energy Independence Fund, Inc. is a close ended equity mutual fund launched and managed by Tortoise Capital Advisors L.L.C. The fund invests in the public equity markets of the North American. It seeks to invest primarily in the energy sector. The fund employs a fundamental analysis with a bottom up stock picking approach with focus on factors like quantitative, qualitative, and relative value factors to create its portfolio. Tortoise Energy Independence Fund, Inc. was formed on July 26, 2005 2012 is domiciled in the United States.

Full NDP Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this NDP vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NDP vs SCHDNDP vs JEPINDP vs ONDP vs KONDP vs MAINNDP vs JNJNDP vs ABBVNDP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.